 |
Guidelines
and clinical standards of care for people with diabetes in care
homes |
| |
New guidelines from the Northern Ireland Guidelines
and Audit Implementation Network - GAIN (NHS Evidence) |
| |
|
|
Insulin
'partner' offers clue to prevent heart damage in diabetic patients |
| |
Scientists have uncovered a new molecule that
could protect diabetes patients from the heart damage associated
with insulin treatment (Leeds University) |
| |
|
|
New
research may suggest another role for a molecule to help prevent
heart damage |
| |
Scientists have some evidence that a molecule
called C-peptide may help prevent some of the cardiovascular complications
that people with diabetes are at risk from (Diabetes UK) |
| |
|
|
Glycemic
control and cardiovascular disease in 7454 patients with type
1 diabetes: an observational study from the Swedish National
Diabetes Register (NDR) |
| |
This observational study of patients in modern
everyday clinical practice demonstrates progressively increasing
risks for CHD and CVD with higher HbA1c independently of traditional
risk factors (Diabetes Care) |
| |
|
|
Post
project review report - diabetes in pregnancy |
| |
This report presents findings of a post project
review on the national confidential enquiry into diabetes in pregnancy
(Centre for Maternal and Child Enquiries) |
| |
|
|
Mayo-led
Research Team Develop Agents That Keep Insulin Working Longer |
| |
More than half a century after researchers identified
a promising way to treat diabetes based on blocking the breakdown
of insulin in the body, a research team led by a scientist at the
Mayo Clinic campus in Florida have developed potent molecules that
can do just that (Mayo Clinic) |
| |
|
|
Glycemic
control in children with Type 1 diabetes in Wales - the influence
of the Pediatric Diabetes Specialist Nurse |
| |
Improvement in glycemic control has occurred.
Worse control is seen associated with greater prescribed insulin
dose in older children. Appointing PDSNs was associated with improved
glycemic control amongst adolescents (Diabetes Care) |
| |
|
|
Novel
Artificial Pancreas Successfully Controls Blood Sugar More Than
24 Hours |
| |
An artificial pancreas system that closely mimics
the body's blood sugar control mechanism was able to maintain near-normal
glucose levels without causing hypoglycemia in a small group of
patients (Science Daily) |
| |
|
|
Prescription
Tattoos: Coming to a Pharmacy Near You |
| |
It might be time for a trip to the tattoo parlor.
Medical tattoos could soon monitor key vitals, including glucose
levels (Discovery News) |
| |
|
|
HDL
and LDL cholesterol significantly influence [beta]-cell function
in type 2 diabetes mellitus |
| |
Recent findings indicate that HDL protects ß-cells
from cholesterol-induced ß-cell dysfunction, stress-induced apoptosis and islet inflammation. As the protective
properties of HDL are compromised in patients with metabolic syndrome
and T2DM, dysfunctional HDL metabolism could contribute to the
pathogenesis of T2DM (Lipidology) |
| |
|
|
Whole-Grain,
Cereal Fiber, Bran, and Germ Intake and the Risks of All-Cause
and Cardiovascular Disease–Specific Mortality Among Women With Type 2 Diabetes Mellitus |
| |
Whole-grain and bran intakes were associated
with reduced all-cause and CVD-specific mortality in women with
diabetes mellitus (Circulation) |
| |
|
|
Enhanced
Accuracy of Continuous Glucose Monitoring by Online Extended
Kalman Filtering |
| |
Realistic simulations show that the new enhanced
calibration method significantly improves the accuracy of CGM signals,
suggesting potential benefits by its inclusion in real-time applications
of CGM devices (Diabetes Technology & Therapeutics) |
| |
|
|
Funding
of up to Euro 800,000 available |
| |
EFSD/Lilly European Diabetes Research Programme
(European Foundation for the Study of Diabetes) |
| |
|
|
Role
of saxagliptin as monotherapy or adjunct therapy in the treatment
of type 2 diabetes |
| |
In a phase 3 clinical trials program of 24 weeks
duration, saxagliptin was studied in 6 multicenter, multinational,
randomized, controlled studies and in combination with 3 of the
most commonly administered oral antidiabetic drugs: metformin,
glyburide and a thiozolidinedione (Therapeutics and Clinical Risk
Management) |
| |
|
|
Glaxo
Said to Pay $60 Million in Avandia Settlements (Update2) |
| |
GlaxoSmithKline Plc agreed to pay about $60
million in the first settlements of lawsuits alleging the company’s Avandia diabetes drug causes heart attacks and strokes in some users, people
familiar with the accords said. (Bloomberg) |
| |
|
